X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Unichem Lab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs UNICHEM LAB - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA UNICHEM LAB DISHMAN PHARMA/
UNICHEM LAB
 
P/E (TTM) x 25.1 33.2 75.5% View Chart
P/BV x 3.3 3.5 95.6% View Chart
Dividend Yield % 0.7 0.5 122.4%  

Financials

 DISHMAN PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
UNICHEM LAB
Mar-16
DISHMAN PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs374334 112.1%   
Low Rs129174 74.1%   
Sales per share (Unadj.) Rs197.8146.9 134.6%  
Earnings per share (Unadj.) Rs21.211.9 178.3%  
Cash flow per share (Unadj.) Rs34.716.2 214.5%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.8 100.9%  
Book value per share (Unadj.) Rs179.9105.1 171.1%  
Shares outstanding (eoy) m80.6990.84 88.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.31.7 73.6%   
Avg P/E ratio x11.921.4 55.6%  
P/CF ratio (eoy) x7.215.7 46.2%  
Price / Book Value ratio x1.42.4 57.9%  
Dividend payout %9.416.8 56.1%   
Avg Mkt Cap Rs m20,30623,073 88.0%   
No. of employees `0000.85.7 14.6%   
Total wages/salary Rs m5,3552,558 209.3%   
Avg. sales/employee Rs Th19,252.72,352.5 818.4%   
Avg. wages/employee Rs Th6,459.5450.9 1,432.6%   
Avg. net profit/employee Rs Th2,064.1190.4 1,083.8%   
INCOME DATA
Net Sales Rs m15,96113,346 119.6%  
Other income Rs m265192 138.3%   
Total revenues Rs m16,22613,538 119.9%   
Gross profit Rs m4,1031,639 250.3%  
Depreciation Rs m1,091390 279.6%   
Interest Rs m94429 3,279.2%   
Profit before tax Rs m2,3341,412 165.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-4 -29.7%   
Extraordinary Inc (Exp) Rs m0-35 0.0%   
Tax Rs m624293 213.1%   
Profit after tax Rs m1,7111,080 158.4%  
Gross profit margin %25.712.3 209.3%  
Effective tax rate %26.720.7 128.9%   
Net profit margin %10.78.1 132.4%  
BALANCE SHEET DATA
Current assets Rs m11,0185,979 184.3%   
Current liabilities Rs m9,5172,432 391.3%   
Net working cap to sales %9.426.6 35.4%  
Current ratio x1.22.5 47.1%  
Inventory Days Days11063 175.2%  
Debtors Days Days3560 57.7%  
Net fixed assets Rs m16,3046,403 254.6%   
Share capital Rs m161182 88.8%   
"Free" reserves Rs m12,9079,293 138.9%   
Net worth Rs m14,5169,548 152.0%   
Long term debt Rs m4,189230 1,818.3%   
Total assets Rs m29,80512,843 232.1%  
Interest coverage x3.550.0 6.9%   
Debt to equity ratio x0.30 1,196.1%  
Sales to assets ratio x0.51.0 51.5%   
Return on assets %8.98.6 103.2%  
Return on equity %11.811.3 104.2%  
Return on capital %17.514.3 122.3%  
Exports to sales %24.829.2 84.8%   
Imports to sales %3.76.3 58.9%   
Exports (fob) Rs m3,9563,900 101.5%   
Imports (cif) Rs m596847 70.4%   
Fx inflow Rs m4,9524,356 113.7%   
Fx outflow Rs m6971,162 60.0%   
Net fx Rs m4,2553,194 133.2%   
CASH FLOW
From Operations Rs m2,7861,119 249.0%  
From Investments Rs m-1,529-853 179.2%  
From Financial Activity Rs m-941-334 281.6%  
Net Cashflow Rs m316-68 -463.3%  

Share Holding

Indian Promoters % 61.4 50.1 122.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 15.1 24.5%  
FIIs % 12.7 3.0 423.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 31.7 69.7%  
Shareholders   46,261 20,176 229.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  BIOCON LTD  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits 36,000-Mark; Infosys & Tata Steel Top Gainers(09:30 am)

Asian equities are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.82% while the Hang Seng is up 1.26%. The Nikkei 225 is trading up by 0.93%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - SANOFI INDIA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS